First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer Post author: Post published:April 26, 2024 Post category:uncategorized The real-world safety and efficacy of sacituzumab govitecan (SG) against metastatic triple-negative breast cancer. You Might Also Like Measles vaccine more likely to be completely ineffective in children born by C-section May 13, 2024 Gut bacteria may influence immunotherapy success in mesothelioma patients September 5, 2024 St. Jude researchers uncover NLRC5’s role in immune response and cell death June 16, 2024